This drug was evaluated in a double-blind, randomized, multinational trial, the Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitors with ACE Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF trial). Here, ACE is linked to heart failure.